Andrew Stewart Plump Sells 19,651 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Key Points

• Insider sale: Andrew Stewart Plump sold 19,651 Takeda shares for approximately $363,347 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 6.99% to 261,656 shares. He had also sold 165,393 shares earlier in August.
• Market and earnings performance: Takeda shares traded near $18.17, close to the 52-week high of $18.90. The company reported quarterly EPS of $0.47, beating estimates by $0.30, while revenue of $7.50 billion exceeded consensus expectations.
• Analyst sentiment remains mixed: Ratings range from buy to sell, with MarketBeat’s consensus rating at “Hold.” Institutional investors own 9.17% of the company, with several major firms increasing their positions.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Andrew Stewart Plump sold 19,651 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $18.49, for a total transaction of $363,346.99. Following the completion of the sale, the insider directly owned 261,656 shares in the company, valued at approximately $4,838,019.44. The trade was a 6.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Monday, August 10th, Andrew Stewart Plump sold 165,393 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock traded up $0.04 during midday trading on Friday, reaching $18.17. 1,479,067 shares of the stock were exchanged, compared to its average volume of 3,162,046. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm has a market cap of $58.22 billion, a PE ratio of 53.44 and a beta of -0.08. The company's fifty day moving average is $16.75 and its 200-day moving average is $17.18.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.17 by $0.30. The firm had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TAK. Weiss Ratings lowered Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, July 30th. Wall Street Zen upgraded Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Finally, Zacks Research raised Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold".

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds have recently made changes to their positions in TAK. Royal Bank of Canada raised its position in Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 441,054 shares of the company's stock valued at $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Takeda Pharmaceutical by 43.6% during the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company's stock valued at $2,911,000 after purchasing an additional 59,442 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock valued at $79,120,000 after purchasing an additional 692,404 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Takeda Pharmaceutical by 4.1% during the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company's stock valued at $1,230,000 after buying an additional 3,239 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in shares of Takeda Pharmaceutical during the 2nd quarter valued at about $351,000. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source